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Androgens increase skeletal muscle mass, but their clinical use is hampered by lack of tissue se-
lectivity and subsequent side-effects. Selective androgen receptor modulators (SARMs) elicit mus-
cle-anabolic effects while only sparingly affecting reproductive tissues. The SARM GTx-024 (eno-
bosarm) is being investigated for cancer cachexia, sarcopenia, and muscle wasting diseases. Here,
we investigate the role ofmuscle androgen receptor (AR) in the anabolic effect of GTx-024. Inmice
lacking AR in the satellite cell lineage (satARKO), the weight of the androgen-sensitive levator ani
muscle was lower, but decreased further upon orchidectomy. GTx-024 was as effective as dihy-
drotestosterone (DHT) in restoring levator ani weights to sham levels. Expression of the muscle-
specific androgen-responsive genes S-adenosylmethionine decarboxylase and myostatin was de-
creased by orchidectomy and restored by GTx-024 and DHT in control mice, while expression was
low and unaffected by androgen status in satARKO. In contrast, insulin-like growth factor IEa
expression was not different between satARKO and control muscle, decreased upon castration,
and was restored by DHT and GTx-024 in both genotypes. These data indicate that GTx-024 does
not selectively modulate AR in the satellite cell lineage and that cells outside this lineage remain
androgen-responsive in satARKO muscle. Indeed, residual AR positive cells were present in sa-
tARKOmuscle, coexpressing the fibroblast-lineage marker vimentin. AR positive, muscle-resident
fibroblasts could therefore be involved in the indirect effects of androgens on muscle. In conclu-
sion, both DHT and GTx-024 target AR pathways in the satellite cell lineage, but cells outside this
lineage also contribute to the anabolic effects of androgens.
Androgens play important roles in diverse biologicalprocesses such as development and maintenance of
the male phenotype. In addition, they have effects on sev-
eral nonreproductive tissues including bone, smoothmus-
cle, and skeletal muscle (1–3). Their biological effects are
exerted by activating the androgen receptor (AR). This
ligand-inducible transcription factor binds to specific
DNA sequences called androgen response elements
(AREs) to regulate transcription of target genes (4).
Despite their well-documented effect of increasing
muscle mass and strength (5, 6), the clinical use of andro-
gens is limited due to a lack of tissue selectivity and po-
tential subsequent side effects. Together with their poor
oral bioavailability and pharmacokinetic profile, this has
stimulated the development of selective AR modulators
(SARMs). A well-established body of evidence supports
their in vivo tissue selectivity in animalmodels, as assessed
by their ability to increase levator ani muscle weight and
bone mineral density (BMD) while only sparingly affect-
ing the weight of androgenic tissues (7).
GTx-024 (enobosarm) is a nonsteroidal SARM which
increasesmusclemass with only limited effects on seminal
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vesicles in preclinical studies (8). Trials in healthy elderly
men (9) and in cancer patients with muscle wasting (10)
have reported increased lean body mass and improved
physical function in the GTx-024 treated groups com-
pared to placebo, making this compound a strong candi-
date for further clinical development.
Skeletal muscle is a complex tissue and the impact of
androgens canbemediatedviaoneor all of theARpositive
cell types. Indeed, androgens can have direct effects on
cells of the satellite cell lineage including satellite cells,
myoblasts, andmyocytes, which all express the AR (1, 11,
12). In addition, indirect effects may contribute to the
eventual muscle hypertrophy, with endothelial cells and
fibroblasts within the muscle being candidate target cells
since AR expression has been reported in these cell types
(13, 14).
Whether the anabolic effect of GTx-024 on muscle is
due to selective action on muscle cell AR is presently un-
known. To further clarify this issue, we performed a cas-
tration and drug replacement study in mice selectively
lacking theAR in satellite cells and hence inmyoblasts and
myocytes (satARKO, satellite cell-specific AR knockout).
The nonaromatizable androgen dihydrotesterone (DHT)
was used as a positive control.
Materials and Methods
Animals
Mice with a satellite cell-specific knockout of the AR (sa-
tARKO) (ARfl/Y;MyoD-iCre/-) and control mice (ARfl/Y;
MyoD-iCre-/-) (C57BL/6J genetic background) were generated
as described elsewhere (15). The animals were housed in stan-
dard cages at 20°C with a 12h-dark/light cycle according to our
institutional guidelines. They had ad libitum access to tap water
and standardchow.Offspringwereweanedat3weeksof ageand
genotyped by PCR-based analysis of DNA samples obtained via
tail biopsy. The experimental protocol was conducted with ap-
proval of the KU Leuven ethical committee (P078–2010).
Experimental design
At 12 weeks of age, male mice were randomly divided into 4
groupswhich each contained 8mice per genotype. Animalswere
weighed and body composition was assessed by whole-body du-
al-energy X-ray absorptiometry (DXA). In group 1, mice were
sham-operated (sham) under sodium pentobarbital anesthesia.
In groups 2, 3, and 4, mice were orchidectomized (orx). Mice
from groups 3 and 4 were treated with 7 mg/kg/d dihydrotes-
tosterone (DHT) (#10300 from Sigma-Aldrich, St. Louis, MO,
USA) or 3 mg/kg/d GTx-024 (#43974 from Sigma-Aldrich) for
twoweeks. The drugswere dissolved in dimethylsulfoxide-poly-
ethylene glycol 300 (1:9, vol/vol) and administered via daily sub-
cutaneous injections in the cervical region. The sham and orx
animalswere treatedwithvehicle during the treatmentperiod.At
the end of the treatment, animals were weighed and body com-
position was assessed by whole-body DXA. Seminal vesicles,
levator ani muscle as well as several limb muscles (gastrocne-
mius, extensor digitorum longus, soleus) were collected and
weighed after euthanasia by cardiac puncture.
Dual-energy X-ray absorptiometry
Whole body lean and fatmasswere analyzed in vivo using the
PIXImusmouse densitometer (LunarCorp.,Madison,WI, USA)
with ultrahigh resolution (0.18 0.18 pixels, 1.6 line pairs/mm)
and software version 1.45.
Serum IGF-I measurement
After acid-ethanol extraction, serum IGF-I concentrations
were measured by an in-house RIA in the presence of an excess
of IGF-II (25 ng/tube) (16).
Quantitative real-time PCR
Total RNA was extracted from murine muscle using TRIzol
reagent (Invitrogen) according to the manufacturer’s protocols.
After digestion with DNase I (Fermentas, St Leon-Rot, Ger-
many), cDNAwas synthesized from 300 ng (levator ani muscle)
or 1 g (gastrocnemius muscle) RNA using the RevertAid M-
MuLV Reverse Transcriptase kit (Fermentas) and random hex-
amer primers (Fermentas). The PCR reaction mixtures (10 l)
contained 1x Platinum SYBR Green qPCR SuperMix-UDG (In-
vitrogen), 0.15 M of each primer, and 50 nM ROX Reference
Dye (Invitrogen). The 7500FastReal-TimePCR system (Applied
Biosystems, Foster City, CA, USA) was used with the ‘Fast RT-
PCR’ two-step protocol (2 minutes at 50°C, 20 seconds at 95°C
and 40 cycles of 3 seconds at 95°C and 30 seconds at 60°C). The
primer sequences are listed in
a href“http://press.endocrine.org/doi/suppl/10.1210/
en.2015–1479/suppl_file/en-15–1479.pdf”Supplemental Ta-
ble 1. All primers were designed to hybridize to separate exons,
and generation of single correct ampliconswas checked byDNA
Table 1. Antibody Table. Details of the primary antibodies used for fluorescent
immunohistochemistry.
Peptide/protein target Antigen sequence (if known) Name of Antibody
Manufacturer, catalog #, and/or
name of individual providing the antibody
Species raised in;
monoclonal or polyclonal
Dilution
used
Androgen receptor (AR) Synthetic peptide derived from
near N-terminus of human AR
Rabbit Anti-Human Androgen Receptor (AR)
Monoclonal Antibody (Clone SP107)
Spring Bioscience; M4070 Rabbit monoclonal 1:300
Myogenin Recombinant protein containing
rat myogenin amino acid 30  224
Anti-Myogenin antibody [F5D] Abcam; ab1835 Mouse monoclonal 1:50
CD31 Synthetic peptide corresponding to
C terminus of mouse CD31
Anti-CD31 antibody Abcam; ab28364 Rabbit polyclonal 1:500
Vimentin Synthetic peptide corresponding to
residues surrounding Arg45 of human vimentin
Vimentin (D21H3) XP Rabbit mAb Cell Signaling Technology; 5741 Rabbit monoclonal 1:600
Laminin Protein purified from the basement
membrane of Englebreth Holm-Swarm (EHS) sarcoma (Mouse)
Anti-Laminin antibody Abcam; ab11575 Rabbit polyclonal 1:300
Pax7 Purified internal fragment of human
recombinant PAX7 expressed in E.Coli
PAX7 Antibody Thermo Scientific; PA1–117 Rabbit polyclonal 1:500
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sequencing and in melting curve assays. Gene expression values
are expressed relative to the levels of 18S rRNA.
Luciferase reporter assay
MouseC2C12myoblasts were purchased from theAmerican
Type Culture Collection (ATCC, Manassas, VA, USA) and cul-
tured at 37°C and 5%CO2 in Dulbecco’s Modified Eagle’s Me-
dium (DMEM) containing 4,5 g/l glucose, 4 mM L-glutamine,
and penicillin (100 IU/ml)-streptomycin (100 g/ml) (Sigma-Al-
drich), and supplementedwith10%fetal calf serum(Invitrogen).
For transfection experiments, cells were seeded in 96-well plates
at a density of 104 cells per well in DMEM supplemented with
5% charcoal-stripped serum (Sigma-Aldrich) and transiently
transfected using X-tremeGENE transfection reagent (Roche,
Basel, Switzerland)with 10 ng of expression plasmid for full-size
humanAR (17), 100ngof luciferase reporter plasmid containing
four copies of the ARE of interest, and 10 ng of -galactosidase
expression plasmid (Stratagene, La Jolla, CA, USA), which
served as an internal control for transfection efficiency. The lu-
ciferase reporter plasmids were generated as described before
(18), and theARE sequences are listed elsewhere (15). Cells were
lysed after stimulation for 24 hours with 100 nMDHT or GTx-
024 in the presence or absence of 100 M MDV3100
(#SRP016825M from Sequoia Research Products, Pangbourne,
UK), and luciferase and-galactosidase activitiesweremeasured
and calculated as previously described (19).
Double antibody fluorescent
immunohistochemistry
Double antibody fluorescent immunohistochemistry was
performed as described previously (20). Briefly, levator ani and
gastrocnemius muscles were fixed in 10% neutral buffered for-
malin (Sigma-Aldrich) overnight at 4°C, rinsed with PBS and
then stored in 70% ethanol at 4°C. After embedding into par-
affin wax, 5 m sections were cut onto micro slides, deparaf-
finized, rehydrated, and subjected to heat-induced antigen re-
trieval in a decloaking chamber containing 0.01Mcitrate buffer.
The tissue sections were then incubated with 3% hydrogen per-
oxide in methanol for 30 minutes at room temperature to block
endogenous peroxidase activity, rinsed with water, and blocked
for 30 minutes in goat serum (Biosera, Kansas City, MO, USA)
diluted 1:4 in Tris-buffered saline (TBS; 50 mM Tris pH 7.4,
0.85% saline) containing 5% bovine serum albumin (BSA). Pri-
mary antibodies were diluted in goat serum/TBS/BSA and incu-
bated at 4°C overnight. Details of the primary antibodies are
provided in Supplemental Table 2. Secondary antibody (goat
antirabbit peroxidase [Abcam, ab7171] or goat antimouse per-
oxidase [Abcam, ab6823])was diluted 1:500 in goat serum/TBS/
BSA and applied to sections for 45minutes at room temperature.
Finally, slides were incubated with the Tyramide Signal Ampli-
fication™ kit (Perkin Elmer, Waltham, MA, USA; Fluorescein
forARandCyanine 3 for the othermarkers) for 10minutes, then
with DAPI (Sigma-Aldrich) diluted 1:500 in TBS to enable nu-
clear counterstaining. Washes between the several incubations
were performed three times for 3 minutes each using TBS. Im-
munostaining of negative controls, which did not show any an-
tiserum immunolabeling, included sequential elimination of ei-
ther the primary or secondary antibody from the staining
procedure. Sectionswere examinedusingaZeissLSM510Meta-
confocal microscope equipped with a digital camera and images
were analyzed by ImageJ software. The percentage of AR posi-
tive cells corresponding to fibroblasts (identifiedasvimentinpos-
itive) in the LA was calculated out of 286 73 AR positive cells
per animal. All procedures were carried out using coded slides to
avoid bias.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
software (Version 6.00 for Windows, San Diego, CA, USA).
Fisher’s exact test was used for categorical variables, while for
ordinal variables Student’s t test and one-way ANOVA were
used to analyze differences between two ormore groups, respec-
tively. Two-way ANOVA was used in experiments with more
than two independent variables. If overall ANOVA revealed sig-
nificantdifference,Bonferroni’s post hoc testwasused toanalyze
differences between groups. All statistical tests were performed
two-tailed.Data are presented asmeans SEM,andP .05was
considered statistically significant.
Results
GTx-024 is a tissue-selective compound with
anabolic effect on murine androgen-sensitive
muscle
To validate the doses used and to confirm the tissue-
selectivity of GTx-024 in our experimental setting, a pilot
experiment was performed in which the weight of levator
ani (LA) and seminal vesicles (SV) of control mice were
compared among the different treatment groups. Orchi-
dectomy (orx) at 12 weeks of age led to markedly reduced
LA and SV weights after two weeks, and both DHT and
GTx-024 increased the weight of these organs when drug
treatment was initiated immediately after orx (Figure 1).
However,whereasDHTandGTx-024restoredLAweight
to sham level (Figure 1A), they had a differential effect on
SV weight. Indeed, DHT supplementation fully normal-
ized SV weight, while only partial restoration was ob-
served in the GTx-024-treated group (Figure 1B). Gas-
trocnemius (GASTR)musclemasswas not affected by orx
with or without drug replacement (Supplemental Figure
1A), which correlates with the lower levels of AR protein
(Supplemental Figure 1 B and C). Thus, we conclude that
GTx-024 acts as a SARM with an anabolic effect on LA
muscle equivalent to physiological androgen concentra-
tions in this experimental setting.
Muscle AR is not essential for modulation of
muscle mass by GTx-024
To investigate whether the anabolic effect of GTx-024
is mediated via AR inmuscle cells, we performed the same
castration experiment with drug replacement in the sa-
tARKO model. In these mice, the AR was selectively ab-
lated in the muscle progenitor cells called satellite cells,
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leading to a more than two-fold reduction in LA weight
(15) (sham conditions in Figure 2A).
It is known that lean bodymass or appendicularmuscle
mass in mice is considerably less sensitive than LAmuscle
(11), especially in short-term experiments. Indeed, body
weight and body composition were not different between
the groups, neither at baseline nor after the treatment pe-
riod (Supplemental Figure 2 A and B). In addition, limb
musclemasswasnot different between satARKOandcon-
trol mice and unaffected by orx without or with DHT or
GTx-024, as evidenced by the similar weight of gastroc-
nemius (GASTR), extensor digitorum longus (EDL), and
soleus (SOL) muscles in the different treatment groups
(Supplemental Figure 2C). Therefore, we focused in fur-
ther experiments on perineal muscle, which is widely used
as a read-out for androgens in rodents including in SARM
development (21).
Orx decreased LA mass in control mice, an effect that
was also observed in satARKO mice (Figure 2A). Inter-
estingly, GTx-024 reversed the orx effect on LAmuscle of
satARKO mice, to the same extent as did DHT (Figure
2A). These observations were confirmed in another peri-
neal muscle, the bulbocavernosus (BC) (Figure 2B). As a
control for the in vivo effectiveness of the treatments, the
SV weights for each condition are depicted in Figure 2C.
The rescue of LA mass to sham level observed in cas-
trated DHT- as well as GTx-024-treated satARKO mice
may reflect an indirect nonmuscle AR contribution. Al-
ternatively, residual muscle AR expression could be re-
sponsible for this anabolic response. To elucidate this
question, we measured the expression of S-adenosylme-
thionine decarboxylase 1 (Amd1) and myostatin (Mstn),
two genes shown to be strongly androgen-regulated in
skeletal muscle (15, 22). Indeed, a more than 10-fold re-
duction in Amd1 and Mstn mRNA was observed in LA
muscle of satARKO compared to control mice (sham con-
ditions in Figure 3A and Figure 3B). Orx decreased Amd1
and Mstn transcript levels in control mice but no further
decrease was observed in satARKO mice (Figure 3A and
Figure 3B), demonstrating that muscle AR is sufficient for
androgen regulation of these muscle-specific genes. In ad-
dition, these findings confirm effective disruption of mus-
cle AR in satARKO, at least at the functional level. Orx-
mediated decrease in Amd1 and Mstn mRNA was
reversed by DHT and also by GTx-024 in control mice
(Figure3AandFigure3B), indicating thatGTx-024action
on muscle is, at least in part, direct via muscle AR activa-
tion. Importantly however, neither DHT nor GTx-024
wereable to induceAmd1orMstnexpression in satARKO
LA (Figure 3A and Figure 3B) although they had a clear
effect on muscle mass, supporting the hypothesis of an
indirect nonmuscle AR contribution to muscle mass by
androgens and GTx-024. Similar Amd1 expression pat-
terns were observed inGASTRmuscle (Supplemental Fig-
ure 3A). Mstn transcript levels were however not altered
by orx with or without drug replacement in GASTRmus-
cle, albeit lower in satARKOcompared to control samples
(two-way ANOVA, P .02 for genotype) (Supplemental
Figure 3B).
We previously identified two conserved AREs in the
promotor and in exon 2 of the Mstn gene, referred to as
ARE1 and ARE2, both of them binding the DNA-binding
domain of the AR and conferring androgen-responsive-
ness to a heterologous promotor (15). ARE1 is part of an
ARbinding site found in the chromatin of primary human
myoblasts by ChIP-on-Chip analysis (23). In a transient
transfection assay in the C2C12 muscle cell line, ARE1
and ARE2 based reporter genes displayed responsiveness
to DHT and GTx-024, which was strongly reduced in the
presence of the AR antagonist MDV3100 (Supplemental
Figure 4). Thus, in line with the
above-mentioned in vivo findings,
these in vitro data indicate thatMstn
gene transcription is a good readout
of muscle-specific androgen respon-
siveness, and that muscle AR is in-
volved in the anabolic effect of
GTx-024.
Insulin-like growth factor IEa
(IGF-IEa), an IGF-I isoform locally
expressed within muscle, is an im-
portant positive regulator of muscle
mass (24), and its expression is reg-
ulated by androgens (25, 26). In-
deed, orx decreased IGF-IEa tran-
script levels in LAof controlmice, an
effect that was reversed by DHT and
Figure 1. GTx-024 is a tissue-selective compound with anabolic effect on
muscle. (A and B) Levator ani (LA) muscle weight (A) and seminal vesicle (SV) weight (B) of 14-
week-old control mice that were sham-operated (sham), orchidectomized (orx) or
orchidectomized and treated with dihydrotestosterone (orxDHT) or GTx-024 (orxGTx-024) at
12 weeks of age (n  3). Organ weights were corrected for body weight (BW). Error bars
indicate SEM; *P  .05.
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also by GTx-024 (Figure 3C). Importantly however, the
similar IGF-IEa transcript levels in control and satARKO
sham-operated animals as well as the decrease in IGF-IEa
mRNA in castrated satARKO mice (Figure 3C) indicate
that androgen regulation of IGF-IEa is indirect via non-
muscle AR. Orx-mediated decrease in IGF-IEa mRNA
was reversed by DHT and also by GTx-024 in both ge-
notypes (Figure 3C), opening up the possibility that IGF-I
signaling may be involved in the indirect nonmuscle AR
contribution to muscle mass by androgens and GTx-024.
Serum IGF-I levels were similar in satARKO and control
mice and unaffected by orxwithout orwithDHTorGTx-
024 (Supplemental Figure 5).
Altogether, we conclude that bothmuscle cell and non-
Figure 2. GTx-024 effects on muscle mass in the satARKO model. Levator ani (LA) weight (A), bulbocavernosus (BC) weight (B) and
seminal vesicle (SV) weight (C) of 14-week-old control and satARKO mice that were sham-operated (sham), orchidectomized (orx) or
orchidectomized and treated with dihydrotestosterone (orxDHT) or GTx-024 (orxGTx-024) at 12 weeks of age (n  7–8). Organ weights were
corrected for body weight (BW). Error bars indicate SEM; *P  .05.
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muscle cell AR play a role inDHT andGTx-024 action on
muscle. The tissue-selectivity of GTx-024 is however not
explained by selective targeting of muscle cell AR, as ev-
idenced by retained efficacy in the satARKO model.
Fibroblasts may be involved in indirect androgen
action on muscle
We next examined which cell types within the muscle
other than the muscle cells themselves may mediate the
indirect anabolic effect of androgens. Although AR pro-
tein is expressed predominantly in satellite cells and myo-
nuclei, endothelial cells and fibroblasts within the muscle
have also both been reported to express the AR (13, 14).
Therefore, LAmuscle sections fromcontrol and satARKO
mice were double stained for the AR on the one hand and
for myogenin, CD31 or vimentin (vim) on the other hand
(markers for muscle fibers, endothelial cells and fibro-
blasts, respectively). In control mice, we observed AR
Figure 3. Amd1, Mstn, and IGF-IEa mRNA expression in levator ani muscle. Quantitative real-time PCR analysis of S-
adenosylmethionine decarboxylase (Amd1) (A), myostatin (Mstn) (B), and insulin-like growth factor IEa (IGF-IEa) (C) mRNA in levator ani muscle of
14-week-old control and satARKO mice that were sham-operated (sham), orchidectomized (orx) or orchidectomized and treated with
dihydrotestosterone (orxDHT) or GTx-024 (orxGTx-024) at 12 weeks of age (n  7–8). Error bars indicate SEM; *P  .05.
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nuclei coexpressing not only themuscle markermyogenin
(Figure 4A) but also the fibroblastmarker vim (Figure 4B).
The stainings revealed no coexpression of AR and CD31
(Figure 4C). In satARKO LA muscle, the overall number
of AR cells was considerably reduced (quantification in
Figure 6A), in line with the strongly reducedmRNA levels
reported previously in (15). Still, we observed many re-
mainingARnuclei,which appeared to be located almost
entirely outside of muscle fibers (white arrows in Figure
4A). The nonsatellite cell nature of these remaining AR
nuclei was confirmed by their local-
ization outside of the basal lamina
(Figure 5A) as well as the absence of
Pax7 coexpression (Figure 5B).
Most of theAR nuclei in satARKO
LA were identified as fibroblasts, as
determined by positive staining to
vim (Figure 4B).
A more detailed examination of
the latter double staining revealed
that, while control LA muscle con-
sistsmostly of AR vim- cells (white
arrows in upper panel of Figure 6B)
with some cells being AR vim
(red arrows in upper panel of Figure
6B), the vastmajorityofAR cells in
satARKO LA muscle also express
vim (red arrows in lower panel of
Figure 6B). Quantification of AR
and vim cells is shown in Figure
6C. These findings were confirmed
in GASTR muscle (Supplemental
Figure 6). Altogether, the intranu-
clear presence of AR suggests that fi-
broblasts could be involved in the in-
direct anabolic effect of androgens
on skeletal muscle.
Discussion
Muscle wasting is a hallmark of ag-
ing (27) and also occurs in various
chronic disorders such as cancer (27,
28). Androgens could potentially be
exploited in these patient groups, as
they increase both muscle mass and
strength (5, 6). Their anabolic action
is thought to be mediated by a dual
mechanism, ie, direct activation of
muscle AR as well as indirect action
through nonmuscle AR pathways
(1).However, as androgen treatment
is associated with potential cardio-
vascular and prostate cancer risks,
SARMs were developed as an alter-
native strategy to counteract muscle
Figure 4. Microscopy of cell types identified by double staining for AR and cell
type-specific markers. A, Levator ani (LA) muscle sections from 8-week-old control and
satARKO mice were stained for AR (green), myogenin (red), and DAPI (blue). Myogenin is a
marker for muscle cells. The remaining AR nuclei in satARKO LA muscle appear to be located
outside of the muscle fibers (white arrows). B, LA muscle sections from 8-week-old control and
satARKO mice were stained for AR (green), vimentin (red), and DAPI (blue). Vimentin (vim) is a
marker for fibroblasts. Positive staining for vim was detected in AR cells (red arrows). C, LA
muscle sections from 8-week-old control and satARKO mice were stained for AR (green), CD31
(red), and DAPI (blue). CD31 is a marker for endothelial cells. CD31 staining was detected around
blood vessels (white arrowheads) and did not colocalize with AR cells (white arrows). Scale bar
20 m.
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atrophy (7). GTx-024 or enobosarm (also known as Os-
tarine and S-22) is clinically well-characterized, and has
consistently demonstrated increases in lean body mass
across various populations (29). The
molecularmechanismsbehind its tis-
sue-selectivity and anabolic action
onmuscle itself however remain elu-
sive. The aim of the present study
was therefore to investigate whether
the anabolic effect ofGTx-024 isme-
diated via AR inmuscle cells. To this
end, we performed a castration and
drug replacement experiment in
mice selectively lacking the AR in
satellite cells and hence in myoblasts
and myocytes (satARKO) (15), and
compared the effects of GTx-024
with those of DHT.
Skeletal muscles differ markedly
in their responsiveness to androgens.
For example, the perineal skeletal
muscles LA and BC are highly an-
drogen responsive and depend on
androgens for their normal mainte-
nance and function, whereas the
limb skeletal muscle EDL is rela-
tively unresponsive to androgens
anddoesnotdependonandrogens to
maintain fiber size (30). In accor-
dance, selective AR ablation in mus-
cle reduces BC/LA but not limbmus-
cle mass (11, 15).
Immunohistochemical staining of
muscle sections revealed that the
BC/LAcomplex containsmuchmore
AR protein than do less responsive
muscles like GASTR or EDL (13,
31), a finding that was confirmed in
this study. Thus, differences in AR
protein content of skeletal muscles
seem to underlie differences in an-
drogen responsiveness. This differ-
ence in androgen sensitivity is illus-
trated by the fact that in this study
twoweeksof treatmentwithDHTor
GTx-024 were sufficient to increase
LA mass in orx animals but not to
alter leanbodymass, in contrastwith
the increase in lean mass observed
upon eight weeks of treatment with
DHT or the structurally related
GTx-007 compound (32). Due to its
high androgen responsiveness, the
LA muscle is widely accepted as
Figure 5. The remaining AR nuclei in satARKO muscle are not satellite cells. A,
Levator ani (LA) muscle sections from 8-week-old control and satARKO mice were stained for AR
(green), laminin (red), and DAPI (blue). Laminin is a structural component of the basal lamina. B,
LA muscle sections from 8-week-old control and satARKO mice were stained for AR (green), Pax7
(red), and DAPI (blue). Pax7 is a marker for satellite cells. The nonsatellite cell nature of the
remaining AR nuclei in satARKO muscle is confirmed by their localization outside of the basal
lamina as well as the absence of Pax7 coexpression. Scale bar 50 m.
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read-out for androgen anabolic action in preclinical and
pharmacological studies including in SARMdevelopment
(21). For this reason, we decided to focus on LAmuscle to
study the mechanisms of GTx-024 action.
A direct role for muscle AR in mediating androgen an-
abolic action was demonstrated by various mouse models
inwhich theARwas specifically ablated inprogenitor (15)
or mature (11, 12) muscle cells. These three models all
showed a muscle phenotype, albeit generally mild. To de-
termine the implication of muscle AR in mediating GTx-
024 action, we assessed the expression of two muscle
genes, Amd1 and Mstn, in response to GTx-024 treat-
ment. Amd1 is a key enzyme in the synthesis pathway of
polyamines, which are increased in rodentmodels ofmus-
cle hypertrophy (33). Mstn is a strong negative regulator
of muscle growth, since disruption of the Mstn gene in-
duces adramatic increase inmusclemass (34).These genes
are androgen-regulated in skeletal muscle, as Amd1 (22)
and Mstn (35) mRNA levels were decreased in orx mice
and restored by testosterone administration. Recently, we
identified muscle AR as a mediator of this androgen reg-
ulation. Indeed, Mstn as well as Amd1 transcript levels
were reduced in satARKOmuscle (15). GTx-024 upregu-
latedmRNA levels of both genes in LAmuscle of castrated
control mice, indicating a role for muscle AR in GTx-024
action.
None of the muscle-specific ARKOmodels fully repro-
duces the muscle phenotype of the global ARKO (22, 36),
suggesting that muscle cells are not the sole target for an-
drogen action in muscle. In accordance, cell-specific over-
expression of wild type AR in skeletal muscle of testicular
feminized (Tfm) rats is not sufficient to rescueBC/LAmass
(37). Additional evidence for indirect androgen action on
muscle is provided by the observation that orx further
decreases BC/LA mass in satARKO mice, an effect that is
fully reversed by DHT supplementation (15). Thus, the
satARKO model could be further exploited to demon-
strate a tissue-selective mechanism via muscle AR. How-
ever, while regulation of themuscle-specific androgen tar-
get genes Amd1 and Mstn was completely ablated in
satARKO, GTx-024 still reversed
the orx effect on BC/LA mass as ef-
ficiently as DHT in vivo. Hence, our
data suggest that GTx-024 action is
both direct via muscle AR and indi-
rect via nonmuscle AR pathways,
just as for other androgens.
A first potential pathway of indi-
rect androgen action on muscle is by
affecting the nonmuscular fraction
of the tissue. Indeed, AR expression
within the muscle is not restricted to
satellite cells and myonuclei, but has
also been described in endothelial
cells and fibroblasts (13, 14). There-
fore, in this study, LA muscle sec-
tions were double stained for the AR
on theonehandand forCD31or vim
on the other hand (markers for en-
dothelial cells and fibroblasts, re-
spectively). In our conditions,
CD31 cellswere scarce throughout
the LA and did not show AR expres-
sion. However, resident fibroblasts
within the LA express nuclear AR,
thus suggesting that these cells could
be involved in the androgen action
onmuscle. This hypothesis is further
supported by the fact that in sa-
tARKOLAmuscle, which shows an-
drogen responsiveness in the absence
of muscle AR, the vast majority of
Figure 6. Fibroblasts may be involved in indirect androgen action on muscle. A,
Number of AR cells per field in levator ani (LA) muscle sections from 8-week-old control and
satARKO mice (n  3). B, LA muscle sections from 8-week-old control and satARKO mice were
stained for AR (green), vimentin (red), and DAPI (blue). While control LA muscle consists mostly
of AR vim- cells (white arrows in upper panel) with some cells being AR vim (red arrows in
upper panel), the vast majority of AR cells in satARKO LA muscle also expresses vim (red arrows
in lower panel). Scale bar 20 m. C, Percentage of AR cells that stained negatively (white) or
positively (black) for vim was calculated from LA muscle sections from 8-week-old control and
satARKO mice (n  3). Error bars indicate SEM; *P  .05.
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remaining AR cells also expresses vim. Also in GASTR
muscle, vimentin is expressed in some AR cells from
control mice as well as in most AR cells from satARKO
animals. Thus, although our study focused on LAmuscle,
our findings can be extended to limb skeletal muscles.
Several studies support the involvement of muscle fi-
broblasts in the development, maintenance and regener-
ation of muscle structure and function. Mice devoid of
Tcf4, which is abundantly expressed inmuscle fibroblasts
but not in myogenic cells, display an abnormal muscular
morphology, with several muscles being aberrantly split
along with an altered muscle fiber type (38). Similarly,
ablation of Tcf4 during muscle regeneration leads to pre-
mature satellite cell differentiation and smaller myofibers
(39). The exactmechanisms underlying the paracrine con-
trol of myoblast proliferation and differentiation by fi-
broblasts are unclear. Early studies have shown that in
cultures composed of both myogenic and fibroblast-like
cells, myoblasts exhibit a prolonged proliferative phase
resulting in delayed but increased production of fused
myotubes. Subsequent experiments with conditioned me-
dia indicated that the fibroblast-like cells produce soluble
myogenic growth factors, but failed to determine their
identity (40). Recently, FGF-2 was proposed as a possible
mediator, since neutralizing antibodies to FGF-2 were
able to block the fibroblast effects onmyotubes.However,
inhibition due to FGF-2 was only noticed in coculture
experiments allowing direct cell-cell contact between both
cell types and not in conditioned media experiments (41).
Thus, the exact nature and identity of the fibroblast-de-
rived paracrine factors stimulating myogenesis remain
presently unknown.
Although androgen effects on fibroblasts have been in-
tensively studied in prostate cancer (42), androgen action
onmuscle fibroblasts remains tobe investigated.Recently,
amousemodelwas generated inwhich theARwasablated
in mesenchymal cells (43). In these mutant mice, the
BC/LA muscle complex failed to develop. Moreover, as
the number of proliferating undifferentiated myoblasts
was reduced, the authors suggested that the mesenchymal
AR may regulate the proliferation of muscle myoblasts in
a paracrine way (43). Since muscle fibroblasts are from
mesenchymal origin, this study supports the involvement
of fibroblasts in indirect androgen action on muscle. Ad-
ditional evidence is provided by in vitro experiments, in
which androgen treatment of theC3H10T1/2 pluripotent
mesenchymal cell line upregulated myogenic differentia-
tion markers (44). To confirm however that the indirect
pathway, potentially via muscle-resident fibroblasts, af-
fects adult muscle homeostasis, studies using an inducible
Cre-LoxPmodel targeting these fibroblasts (withminimal
changes in other organs) would be required.
Transcript levels of IGF-IEawere not different between
satARKO and control muscle but were decreased upon
castration in both genotypes, indicating indirect androgen
regulation of IGF-IEa via nonmuscle AR. DHT as well as
GTx-024 rescued the orx-mediated decrease in IGF-IEa
mRNA, suggesting that local IGF-I signaling may be in-
volved in the indirect nonmuscle AR contribution to mus-
cle mass by androgens and GTx-024. There were no dif-
ferences in serum IGF-I levels. There is increasing evidence
that, in contrast to circulating IGF-I (45), locally produced
IGF-I is an importantmediator of androgen action inmus-
cle. Indeed, androgen treatment increases and orchidec-
tomydecreases IGF-ImRNAinmuscle (12, 25).However,
as both fibroblasts (46) and muscle cells (47) produce
IGF-I, further studies are needed to determine whether, in
addition to a direct effect on IGF-I production by muscle
cells (26), androgens stimulate IGF-I production by fibro-
blastswith subsequentproliferative effects onneighboring
muscle cells, or alternatively, enhance the secretion of
myogenic factors by fibroblasts which will lead to in-
creased IGF-I production by the muscle cells themselves.
Although in this study we were interested in the local
effects of androgens on muscle, it must be taken into ac-
count that androgensmight also promotemuscle function
by acting on other organs or systems (1, 48). A limited
number of studies have assessed this possibility, focusing
mainly on the effects of androgens on muscle innervation
and, in particular, on the highly androgen-sensitive spinal
motor neurons supplying the LA (49, 50). Although these
studies suggest that the neuronal AR is not crucial for
maintainingLAmass, this has not been confirmedyetwith
a neuron-specific AR knockout model.
In summary, the mechanism of action of GTx-024 on
skeletalmuscle is partly direct viamuscleARactivation. In
addition, part of the anabolic effect seems tobe indirect via
nonmuscle AR pathways. Muscle fibroblasts may play a
role in these indirect pathways, although additional stud-
ies are needed to clarify the exact molecular mechanisms
of this indirect activity.Moreover, further investigation is
required to confirm whether other SARMs exist or can be
designed which have a more muscle-specific action.
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